Priority of SARC studies for selected sub-types. Eligibility SARC 003 –Gem/docetaxel –Osteo/Ewings < 2 prior regimens –Chondrosarcoma 0-X prior regimens.

Slides:

Advertisements

Similar presentations

A Phase II Trial of Perifosine in Patients with Chemo-Insensitive Sarcomas Dejka M. Steinert, MD.

Advertisements

Malignant Bone Tumors by C. Parker Gibbs, Kristy Weber, and Mark T. Scarborough J Bone Joint Surg Am Volume 83(11): November 1, 2001 ©2001 by.

Robert S. Benjamin, M.D. Department of Sarcoma Medical Oncology The SARCOMA Center Department of Sarcoma Medical Oncology The SARCOMA Center Texas Medical.

Soft Tissue Tumors Lucy H. Liu, M.D. Department of Pathology

A pooled analysis of the final results of the two randomized phase II studies comparing Gemcitabine (G) vs Gemcitabine + Docetaxel (G+D) in patients (pts)

Introduction Discussion CT abdomen 3/3/06 lightheadedness and watery diarrhea. TSH was again less than 0.01, and ACTH less than 5. AST and ALT were 240.

SARC016 Phase 2 study of the mTOR inhibitor RAD001 (everolimus) in combination with bevacizumab (avastin) in patients with sporadic and neurofibromatosis.

Janet Eary 1, Janet O'Sullivan 3, Finbarr O'Sullivan 3, E. U. Conrad 2 1. Nuclear Medicine/Radiology, University of Washington, Seattle, WA, United States.

A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing-like sarcoma Coordinating Investigator:

Introduction  Soft Tissue Sarcoma (STS) are a group of highly chemotherapy resistant tumors  Doxorubicin is the only APPROVED 1 st line chemotherapy.

Expression of EGFR, ERRB2, and KIT in Adult Soft Tissue Sarcomas: A Clinicopathological Study of 281 Cases Takuro Wada, O Sato, A Kawai, T Hasegawa Sapporo.

Optimizing the use of trabectedin in the daily clinical practice in ASTS Axel Le Cesne, MD.

Clinical Trials with SARC We’re here to help.. What can SARC do for you? Provide help developing a research idea Provide help with contacting pharma Provide.

PET after Chemotherapy in Rhabdomyosarcoma Connective Tissue Oncology Society November 19, 2005 Michelle L. Klem, Leonard H. Wexler, Ravinder Grewal, Heiko.

November 2006 Phase II Study of Dasatinib in Advanced Sarcoma SARC 009 Coordinating site: University of Michigan.

Setting the scene Louise Soanes TCT Nurse Consultant for AYA The Royal Marsden NHS Foundation Trust.

Challenges in the Treating of Bone and Soft Tissue Sarcomas Margaret von Mehren, MD Director Sarcoma Oncology Fox Chase Cancer Center Philadelphia, PA.

Clinical Trials – An Academic Perspective Mohammed Milhem, MD University of Iowa.

Soft Tissue Tumors Academy of Pathology and Laboratory Medicine of Puerto Rico April 2013 Bruce Horten, M.D. Medical Director Integrated Oncology, New.

A PHASE II TRIAL OF PERIFOSINE IN PATIENTS WITH CHEMO-INSENSITIVE SARCOMAS A SARCOMA ALLIANCE FOR RESEARCH THROUGH COLLABORATION (SARC) STUDY Study Update.

SARC020 – EORTC TRUSTS – A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to.

Maki RG, Wathen JK, Patel SR, Priebat DA,

Systemic therapy More recent agents: Unregistered agents:

1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.

Phase II Study of Dasatinib in Advanced Sarcomas SARC 009 Study PI: Scott Schuetze Registration and eCRF: CRAB Drug supply: BMS.

Osteogenesis imperfecta (compression fractures). OI-blue sclera.

Kara Penney Bone Cancer. Osteosarcoma Chondrosarcoma The Ewing Sarcoma Family of Tumors (ESTFs) Types of Bone Cancer.

Randomized phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas (TRS) Sant P. Chawla,

Bone and soft tissue tumors Imad Fadl-Elmula Al Neelain University.

SARC011/NO21157 Alberto Pappo, M.D. Texas Children’s Cancer Center Houston, TX.

SARC studies: an overview

A Phase II Trial of Perifosine in Patients with Chemo-Insensitive Sarcomas Study Update – November 2008 Dejka Araujo, MD MD Anderson Cancer Center, Houston,

NO OFFENSE INTENDED Why we need investigator-initiated trials.

SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Unresectable Malignant Peripheral Nerve Sheath Tumors.

SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.

Phase II Study of Dasatinib in Advanced Sarcomas SARC009 Sarcoma PI: Scott Schuetze GIST PI: Jon Trent Registration and eCRF: CRAB, Seattle Drug Supply:

CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.

Local Control for Intermediate Risk Rhabdomyosarcoma: Results from D9803 according to Histology, Group, Site and Size A Report from the Children’s.

Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors Brigitte Widemann,

Outcome of chemotherapy in synovial sarcoma (sys) patients (pts): review of 15 clinical trials from EORTCc involving advanced sys compared to other Soft.

Estimating the population-based incidence for sarcoma and GIST in three European regions G. Mastrangelo University of Padova.

Factors Influencing Sarcoma Referral and Treatment William G. Ward, Matthew T. Cline, Fred J. Dorey* Wake Forest University Health Sciences, Winston-Salem,

Using Data to Improve System and Organizational Effectiveness Buck Evans Assistant Superintendent for Operations.

Trabectedin contribution to the treatment of sarcomas Pr JY Blay Centre Leon Berard, Lyon EORTC.

MEASURING CLINICAL EFFICACY IN PHASE II TRIALS Response: Karnofsky, WHO, RECIST Event rate: progression free/survival Time to event: progression/survival.

CTOS years Experience of Management of Malignant Phyllodes Tumor and Breast Sarcoma at Princess Margaret Hospital Princess Margaret Hospital &

Phase II Study of Dasatinib (BMS ) in Advanced Sarcomas and Chordoma Coordinating Center: U Michigan.

1 Sarcoma Ages >= ** Analytic - Initially Diagnosed and/or received all or part of 1st course treatment at.

FOCUS INTERGROUP COLLABORATION AGAINST SARCOMAS (ICAS) FOCUS Biologically targeted therapeuticsBiologically targeted therapeutics Histology specificHistology.

Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing’s Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma.

Suzanne George, MD Instructor in Medicine, Harvard Medical School Clinical Director, Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute.

Sarcoma Mark D. Browning, M.D. ‘77 IUSM-E

CONTRIBUTION OF CHROMOSOME BANDING AND MOLECULAR CYTOGENETIC ANALYSES FOR THE DIAGNOSIS OF SOFT TISSUE AND BONE TUMORS OVER A 6-YEAR-PERIOD Manuel Teixeira,

University of Pennsylvania Department of Orthopaedic Surgery Joseph King, Eileen Crawford, Abass Alavi, Arthur Staddon, Lee Hartner, Richard Lackman and.

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

SARC003 Phase II Study of Gemcitabine & Docetaxel in Recurrent Ewing’s Sarcoma, Osteosarcoma, or Unresectable/Locally Recurrent Chondrosarcoma Elizabeth.

Non-GIST Soft Tissue Sarcoma: Biology and Basics of Targeted Therapy

Advanced Soft Tissue Sarcoma: Current and Future

Investigación en Sarcomas GEIS Spanish Sarcoma Research Group

What's on the Horizon for Soft Tissue Sarcoma?

SARC003: Phase II Study of Gemcitabine & Docetaxel in Recurrent Ewings Sarcoma, Osteosarcoma, or Unresectable/Locally Recurrent Chondrosarcoma Elizabeth.

Opportunities and Challenges in the Management of Advanced STS

Dejka Araujo, MD MD Anderson Cancer Center, Houston, TX

Personalizing Management in the Care of Patients With Advanced Sarcoma

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Volume 18, Issue 10, Pages (October 2017)

Name that bone....

- '1:- bs? a ' I.

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

Presentation transcript:

Priority of SARC studies for selected sub-types

Eligibility SARC 003 –Gem/docetaxel –Osteo/Ewings < 2 prior regimens –Chondrosarcoma 0-X prior regimens SARC 006 –AI/IE –1 st line SARC 007 –Perifosine –<3 prior regimens SARC009 –Dasatinib –0-X prior regimens SARC 011 –R1507 –0-X prior regimens

Chondrosarcoma 1.SARC 003: gemcitabine and docetaxel in bone sarcomas 2.SARC 007: perifosine in chemotherapy insensitive sarcomas (requires documented disease progression for participation) 3.SARC 009: dasatinib in advanced sarcomas (does not require documented disease progression for participation)

Ewings 1.SARC 003: gemcitabine and docetaxel in bone sarcomas 2.SARC 011: IGF-1R for refractory/recurrent subtypes of sarcoma 3.SARC 009: dasatinib in advanced sarcomas

Alveolar soft part sarcoma 1.SARC 007: perifosine in chemotherapy insensitive sarcomas 2.SARC 009: dasatinib in advanced sarcomas 3.SARC 011: IGF-1R for refractory/recurrent subtypes of sarcoma

MPNST 1.SARC 006: chemotherapy in high-grade MPNST 2.SARC 009: dasatinib in advanced sarcomas

Rhabdomyosarcoma 1.SARC 011: IGF-1R for refractory/recurrent subtypes of sarcoma 2.SARC 009: dasatinib in advanced sarcomas

Liposarcoma Extraskeletal Myxoid Chondro SARC 009: dasatinib in advanced sarcomas SARC 011: IGF-1R for refractory/recurrent subtypes of sarcoma

SARC Principles Data trumps “BS” –Rhabdomyosarcoma –Ewings OTHERWISE It’s not over till it’s over –009 precedes 011 –003 precedes 007 In God we trust, everyone else pays cash OR You vote with your feet